138 related articles for article (PubMed ID: 38645737)
1. Periocular Sebaceous Carcinoma: A Case Audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022 to Assess the Diagnostic Utility of PRAME Expression.
Salleh AA; Krishna Y; Coupland SE
Ocul Oncol Pathol; 2024 Apr; 10(1):1-8. PubMed ID: 38645737
[TBL] [Abstract][Full Text] [Related]
2. Comparison of adipophilin and recently introduced PReferentially expressed Antigen in MElanoma immunohistochemistry in the assessment of sebaceous neoplasms: A pilot study.
Donnell SA; LeBlanc RE; Yan S; Parra O; Momtahen S; Sriharan A; Linos K
J Cutan Pathol; 2021 Oct; 48(10):1252-1261. PubMed ID: 33949693
[TBL] [Abstract][Full Text] [Related]
3. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study.
Plaza JA; Mackinnon A; Carrillo L; Prieto VG; Sangueza M; Suster S
Am J Dermatopathol; 2015 Nov; 37(11):809-21. PubMed ID: 26485238
[TBL] [Abstract][Full Text] [Related]
4. Sebaceous Carcinoma of the Eyelid.
Prieto-Granada C; Rodriguez-Waitkus P
Cancer Control; 2016 Apr; 23(2):126-32. PubMed ID: 27218789
[TBL] [Abstract][Full Text] [Related]
5. Eyelid sebaceous carcinoma: clinicopathologic and multiparametric immunohistochemical analysis that includes adipophilin.
Jakobiec FA; Mendoza PR
Am J Ophthalmol; 2014 Jan; 157(1):186-208.e2. PubMed ID: 24112633
[TBL] [Abstract][Full Text] [Related]
6. Androgen Receptor Immunohistochemistry is Superior to PRAME for the Differentiation of Sebaceous Carcinoma From Primary Cutaneous Basaloid Mimics.
Wakefield C; Russell-Goldman E
Am J Dermatopathol; 2024 Apr; 46(4):195-203. PubMed ID: 38488347
[TBL] [Abstract][Full Text] [Related]
7. Perforin expression in eyelid sebaceous carcinomas: a useful and specific immunomarker for the differential diagnosis of eyelid carcinomas.
Mittal R; Araujo I; Czanner G; Coupland SE
Acta Ophthalmol; 2016 Aug; 94(5):e325-30. PubMed ID: 26843360
[TBL] [Abstract][Full Text] [Related]
8. Sebaceous gland carcinoma of the ocular adnexa - variability in clinical and histological appearance with analysis of immunohistochemical staining patterns.
Schmitz EJ; Herwig-Carl MC; Holz FG; Loeffler KU
Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2277-2285. PubMed ID: 28741159
[TBL] [Abstract][Full Text] [Related]
9. PRAME Immuno-Expression in Cutaneous Sebaceous Carcinoma: A Single Institutional Experience.
Cazzato G; Colagrande A; Ingravallo G; Lettini T; Filoni A; Ambrogio F; Bonamonte D; Dellino M; Lupo C; Casatta N; Resta L; Maiorano E; Cascardi E; Marzullo A
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498511
[TBL] [Abstract][Full Text] [Related]
10. HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases.
Hamza MA; Quick CM; Williams HR; Patil NM; Shalin SC
Int J Gynecol Pathol; 2023 Jul; 42(4):338-346. PubMed ID: 36383010
[TBL] [Abstract][Full Text] [Related]
11. Sebaceous carcinoma: clinicopathologic features and diagnostic role of immunohistochemistry (including androgen receptor).
Mulay K; White VA; Shah SJ; Honavar SG
Can J Ophthalmol; 2014 Aug; 49(4):326-32. PubMed ID: 25103648
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor identification in the diagnosis of eyelid sebaceous carcinomas.
Jakobiec FA; Werdich X
Am J Ophthalmol; 2014 Mar; 157(3):687-96.e1-2. PubMed ID: 24333189
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of adipophilin immunostain in periocular carcinomas.
Milman T; Schear MJ; Eagle RC
Ophthalmology; 2014 Apr; 121(4):964-71. PubMed ID: 24290802
[TBL] [Abstract][Full Text] [Related]
14. PRAME immunostain expression in sebaceous lesions, cutaneous carcinomas and adnexal structures.
Ng JKM; Choi PCL; Chow C; Li JJX; Chan AWS; Cheung CMT; Ip ECC; Ng HK; To KF
Pathology; 2022 Oct; 54(6):721-728. PubMed ID: 35644638
[TBL] [Abstract][Full Text] [Related]
15. PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi.
Ng JKM; Choi PCL; Chow C; Li JJX; To KF
Pathol Res Pract; 2024 Jun; 260():155404. PubMed ID: 38878667
[TBL] [Abstract][Full Text] [Related]
16. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens.
Saad M; Cantley R; Hao W; Wang Z; Thomas D; Pantanowitz L; Jin X
Diagn Cytopathol; 2024 Jul; 52(7):362-368. PubMed ID: 38558495
[TBL] [Abstract][Full Text] [Related]
17. PRAME expression in melanocytic lesions of the conjunctiva.
Šekoranja D; Hawlina G; Pižem J
Histopathology; 2021 Dec; 79(6):989-996. PubMed ID: 34268800
[TBL] [Abstract][Full Text] [Related]
18. Preferentially Expressed Antigen in Melanoma Immunohistochemistry Labeling in Uveal Melanomas.
Ahmadian SS; Dryden IJ; Naranjo A; Toland A; Cayrol RA; Born DE; Egbert PS; Brown RA; Mruthyunjaya P; Lin JH
Ocul Oncol Pathol; 2022 Jun; 8(2):133-140. PubMed ID: 35959159
[TBL] [Abstract][Full Text] [Related]
19. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin.
Elsensohn A; Hanson J; Ferringer T
J Cutan Pathol; 2021 Sep; 48(9):1150-1155. PubMed ID: 33719089
[TBL] [Abstract][Full Text] [Related]
20. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
Googe PB; Flanigan KL; Miedema JR
Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
